Thursday, June 24 – Arlington, VA – The Digital Therapeutics Alliance (DTA) is pleased to announce the selection of Andy Molnar as the organization’s incoming Chief Executive Officer to lead the Alliance into its next phase of growth.
“Andy’s deep knowledge of the digital therapeutics industry, his expertise in market access for DTx products and his vision for DTA makes him the ideal CEO to lead us into the future. The Board is excited to partner with Andy as he executes on DTA’s important strategic priorities,” said Debra Reisenthel, Chair of the DTA Board of Directors and Founding CEO of Freespira.
As the leading international organization advancing evidence-based digital therapeutics, DTA is committed to broadening the understanding, adoption, and integration of clinically evaluated digital therapeutics with patients, clinicians, payors, and policymakers through education, advocacy, and cross-industry collaboration. With the DTx industry experiencing global growth, DTA has seen membership grow by 30% in the last six months. During this critical stage for the industry, DTA is expanding its capacity to lead international initiatives that will enable the clinical, organizational, and financial integration of DTx products into mainstream healthcare.
“This is an exceptionally exciting time for the digital therapeutics industry,” said Andy Molnar. “Alongside the members we serve, I look forward to driving the industry forward to help realize the massive opportunity digital therapeutics will bring to improve lives and health outcomes and streamline care.”
Andy has extensive experience in market access and has maintained a particular focus on making accessible and affordable solutions to resolve major gaps in healthcare. He most recently served as the Vice President of Market Access & Government Affairs for Cognoa, a DTA member company developing digital diagnostics and therapeutics for behavioral health conditions.
DTA’s Executive Director, Megan Coder, is transitioning to a new global leadership role within the organization, based in Europe, where she will expand DTA’s efforts related to international policy, lead the development of new content and resources, and grow cross-industry collaborative partnerships in support of DTA member goals.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.
Tuesday, June 15 – Arlington, VA – To meet healthcare decision makers’ growing need for more consistency and clarity on how to evaluate, use, and benefit from digital therapeutics (DTx), the Digital Therapeutics Alliance (DTA) is leading the development of the DTx Value Assessment & Integration Guide.
This resource will provide a foundational template for entities undertaking the development of pathways to assess and integrate DTx products into clinical practice.
Over the last year, DTA has worked with members, our Payor Advisory Board, and Clinician Advisory Group to inform the development of this resource, which will provide a framework to help healthcare decision makers (HCDMs):
This summer, DTA is soliciting feedback from a targeted group of HCDMs, including payors, employers, governments, evaluators, health system administrators, and clinical leaders to review key aspects of this Guide and ensures it meets HCDM needs.
If you are a healthcare decision maker and would like to participate in this targeted feedback period, please send a message including your name, organization, position, and country to valueframework@dtxalliance.org.
Following this comment period, the DTx Value Assessment & Integration Guide will undergo final revisions and is expected to be available to the public later this year.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.
Thursday, June 3 – Arlington, VA – The Digital Therapeutics Alliance (DTA) is pleased to welcome Owen McCarthy, President and Co-Founder of MedRhythms, to the DTA Board of Directors. In support of DTA’s work to transform global healthcare by advancing digital therapeutics (DTx), the Board provides critical guidance related to the strategy and direction of the organization.
The DTA Board of Directors includes:
“It is a great honor to serve on the DTA Board of Directors,” shares Owen McCarthy. “I look forward to building on my perspective as a DTx manufacturer to help us continue elevating the industry to reach the many patients that need us.”
As DTx industry leaders, DTA member efforts are instrumental in providing patients and caregivers, clinicians, policy and healthcare decision makers with reliable resources to meaningfully integrate digital therapeutics into practice and transform global healthcare.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.